{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:36Z","timestamp":1791245196875,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous immunoglobulin (IVIg) is widely used to treat primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, and other disorders. Although effective in maintaining IgG trough levels and reducing infections, its safety profile requires further characterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A large-scale pharmacovigilance study was conducted using the U.S. FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q4 2024. Four disproportionality methods\u2014reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS)\u2014were applied to detect adverse event signals. Weibull modeling was used to assess temporal risk patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 76,138 IVIg-associated reports were identified. Common events included infusion-site reactions (swelling, erythema, pain), infections (upper respiratory tract infection, bronchitis, pneumonia, influenza, urinary tract infection), and systemic reactions (pyrexia, chills, hypersensitivity, headache, asthenia, nausea, vomiting). Several novel potential safety signals emerged, including blood pressure\u2013related events (hypertension and hypotension), weight changes (loss and gain), and falls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world FAERS data confirm the established tolerability of IVIg while highlighting rare but clinically important safety signals, particularly hemolytic anemia and aseptic meningitis. These findings warrant further clinical investigation to optimize monitoring and promote safer therapeutic use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1724196","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:59:35Z","timestamp":1767769175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics of adverse events and clinical risks of intravenous immunoglobulin: a pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhen","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40259-013-0044-3","article-title":"Immune Globulin (Human) 10 % liquid: a review of its use in primary immunodeficiency disorders.","volume":"27","author":"McCormack","year":"2013","journal-title":"BioDrugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and Safety of Privigen(\u00ae) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: results of a Prospective, Single-Arm, Open-Label Phase Iii Study (the Prima Study).","volume":"18","author":"L\u00e9ger","year":"2013","journal-title":"J Peripher Nerv Syst."},{"key":"B3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10875-010-9373-x","article-title":"Tolerability of a New 10% liquid immunoglobulin for intravenous use, privigen, at different infusion rates.","volume":"30","author":"Sleasman","year":"2010","journal-title":"J Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1007\/s10875-014-0070-z","article-title":"Clinical experience with an L-Proline\u2013Stabilized 10 %Intravenous Immunoglobulin (Privigen\u00ae): Real-Life Effectiveness and Tolerability.","volume":"34","author":"Dorsey","year":"2014","journal-title":"J Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","article-title":"Safety and efficacy of privigen, a Novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.","volume":"29","author":"Stein","year":"2009","journal-title":"J Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2215\/CJN.04540709","article-title":"Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly Hla sensitized patients.","volume":"4","author":"Kahwaji","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/trf.13104","article-title":"Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to rh hemolytic disease.","volume":"55","author":"Christensen","year":"2015","journal-title":"Transfusion."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/trf.15846","article-title":"Isoagglutinin reduction in intravenous immunoglobulin (Igpro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.","volume":"60","author":"Shebl","year":"2020","journal-title":"Transfusion."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1159453","DOI":"10.3389\/fmed.2023.1159453","article-title":"Drug repositioning prediction for psoriasis using the adverse event reporting database.","volume":"10","author":"Ko","year":"2023","journal-title":"Front Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"131819","DOI":"10.1016\/j.ijcard.2024.131819","article-title":"Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the fda adverse event reporting system (Faers).","volume":"402","author":"Al-Yafeai","year":"2024","journal-title":"Int J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ymthe.2023.03.003","article-title":"Adverse event reporting to Us Food and Drug administration and risk evaluation and mitigation strategies.","volume":"31","author":"Thompson","year":"2023","journal-title":"Mol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e44883","DOI":"10.1097\/MD.0000000000044883","article-title":"A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: analysis of the FDA adverse event reporting system (Faers) Database.","volume":"104","author":"Ma","year":"2025","journal-title":"Medicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14740338.2023.2251382","article-title":"Post-Marketing Safety of Anti-Il-5 Monoclonal Antibodies (Mabs): An Analysis of the Fda Adverse Event Reporting System (Faers).","volume":"23","author":"Zou","year":"2023","journal-title":"Expert Opin Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"668765","DOI":"10.3389\/fphar.2021.668765","article-title":"Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances.","volume":"12","author":"Khouri","year":"2021","journal-title":"Front Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e34969","DOI":"10.1016\/j.heliyon.2024.e34969","article-title":"Novel insights into post-marketing aes associated with leuprorelin: a comprehensive analysis utilizing the faers database.","volume":"10","author":"Han","year":"2024","journal-title":"Heliyon."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","article-title":"Borrowing external information to improve bayesian confidence propagation neural network.","volume":"76","author":"Tada","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.46234\/ccdcw2024.066","article-title":"Comparison of statistical signal detection methods in adverse events following immunization - China, 2011-2015.","volume":"6","author":"Xia","year":"2024","journal-title":"China CDC Wkly."},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/trf.18083","article-title":"Incidence of adverse events related to intravenous immunoglobulin therapy in children.","volume":"65","author":"C\u00f4t\u00e9","year":"2025","journal-title":"Transfusion."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy.","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/bloodadvances.2020002253","article-title":"Treatment-associated hemolysis in kawasaki disease: association with blood-group antibody titers in ivig products.","volume":"4","author":"Bruggeman","year":"2020","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1111\/trf.13198","article-title":"Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.","volume":"55","author":"Berg","year":"2015","journal-title":"Transfusion."},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12887-024-04546-z","article-title":"Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki Disease.","volume":"24","author":"Cheon","year":"2024","journal-title":"BMC Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/ajhp\/zxac139","article-title":"Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations.","volume":"79","author":"Kobayashi","year":"2022","journal-title":"Am J Health Syst Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2215\/CJN.00500108","article-title":"High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients.","volume":"3","author":"Boll\u00e9e","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/trf.13200","article-title":"Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center.","volume":"55","author":"Bharath","year":"2015","journal-title":"Transfusion."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.3390\/jcm11133571","article-title":"Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment.","volume":"11","author":"Kretowska-Grunwald","year":"2022","journal-title":"J Clin Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/01.NPR.0000843216.79693.7e","article-title":"Possible levetiracetam-induced aseptic meningitis versus viral meningitis: case report and literature review.","volume":"47","author":"Vickery","year":"2022","journal-title":"Nurse Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12883-018-1102-8","article-title":"Immunoglobulin-induced aseptic meningitis: a case report.","volume":"18","author":"Gra\u00e7a","year":"2018","journal-title":"BMC Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12016-024-08989-1","article-title":"Acute aseptic meningitis temporally associated with intravenous polyclonal immunoglobulin therapy: a systematic review.","volume":"66","author":"De Felice","year":"2024","journal-title":"Clin Rev Allergy Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood.2022017283","article-title":"Off-the-shelf cryopreserved platelets for the detection of hit and vitt antibodies.","volume":"140","author":"Kanack","year":"2022","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3346\/jkms.2007.22.4.758","article-title":"A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy.","volume":"22","author":"Lee","year":"2007","journal-title":"J Korean Med Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13075-023-03232-2","article-title":"Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled proderm study.","volume":"26","author":"Aggarwal","year":"2024","journal-title":"Arthritis Res Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"o2409","DOI":"10.1136\/bmj.o2409","article-title":"Spontaneous reporting of post-market safety signals: What evidence should support regulatory action?","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1582050","DOI":"10.3389\/fimmu.2025.1582050","article-title":"Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the faers database.","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future.","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/2042098613490780","article-title":"Monitoring product safety in the postmarketing environment.","volume":"4","author":"Sharrar","year":"2013","journal-title":"Ther Adv Drug Saf."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1724196\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:59:35Z","timestamp":1767769175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1724196\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":36,"alternative-id":["10.3389\/fmed.2025.1724196"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1724196","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1724196"}}